Home › NDC Lookup › J-codes › A9575
A9575

A9575 – Inj gadoterate meglumi 0.1ml · NDC Crosswalk & Billing Units

HCPCS Level II J-code · Medicare Part B drug billing
J-code ● 30 NDCs crosswalked per 0.1 ML $0.090/unit ASP+6%

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 A9575 summary

A9575 is a HCPCS Level II J-code used to bill gadoterate meglumi 0.1ml, billed per 0.1 ML. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with A9575: Clariscan*, Clariscan, Gadoterate Meglumine

Code A9575 Billing unit 0.1 ML Payment limit $0.090/unit NDC-Crosswalk 30 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeA9575
DescriptorInj gadoterate meglumi 0.1ml
Billing unit0.1 ML
Payment limit / unit$0.090
Est. ASP / unit$0.085 est.
Mapped NDCs30
Data periodQ3 2026
Last updated2026-09-20

💊 About Gadoterate Meglumine DRUG GUIDE

Gadoterate meglumine — available as Clariscan, Dotarem, and the generic gadoterate meglumine injection — is used alongside magnetic resonance imaging (MRI) to help visualize the brain (intracranial), spine, and associated tissues.

It works by highlighting areas where the blood-brain barrier is disrupted or where blood vessels are abnormal, making it easier to detect lesions such as tumors, abscesses, and areas of tissue damage.It is approved for use in both adults and pediatric patients, including term newborns (babies born at or after 37 weeks gestation).

All three products share this indication when given intravenously.

Read the full Gadoterate Meglumine drug guide →
Clinical overview from our editorial drug guide for Gadoterate Meglumine. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$0.090
Est. ASP / unit
$0.085 est.
Est. after 2% sequester
$0.088
HCPCS dosage
0.1 ML
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of A9575 = 0.1 ml. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under A9575 WITH EST. MEDICARE PAY

30 NDCs map to A9575. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($0.090/unit) × that package's bill units.
NDC (11-digit)DrugLabelerPackageStrength Bill units Est. pay / pkg NADAC / unit StatusSource
00407-2943-01 CLARISCAN gadoterate meglumine 376.9 mg/mL INJECTION, SOLUTION GE 10 VIAL, GLASS in 1 BOX (0407-2943-01) /... 376.9 mg/mL 1,000 $90.00 — ● Active CMS ASP
00407-2943-02 CLARISCAN gadoterate meglumine 376.9 mg/mL INJECTION, SOLUTION GE 10 VIAL, GLASS in 1 BOX (0407-2943-02) /... 376.9 mg/mL 1,500 $135.00 — ● Active CMS ASP
00407-2943-05 CLARISCAN gadoterate meglumine 376.9 mg/mL INJECTION, SOLUTION GE 10 VIAL, GLASS in 1 BOX (0407-2943-05) /... 376.9 mg/mL 2,000 $180.00 — ● Active CMS ASP
00407-2943-06 CLARISCAN gadoterate meglumine 376.9 mg/mL INJECTION, SOLUTION GE 10 VIAL, GLASS in 1 BOX (0407-2943-06) /... 376.9 mg/mL 500 $45.00 — ● Active CMS ASP
00407-2943-12 CLARISCAN gadoterate meglumine 376.9 mg/mL INJECTION, SOLUTION GE 10 SYRINGE, PLASTIC in 1 BOX (0407-2943-12... 376.9 mg/mL 1,000 $90.00 — ● Active CMS ASP
00407-2943-17 CLARISCAN gadoterate meglumine 376.9 mg/mL INJECTION, SOLUTION GE 10 SYRINGE, PLASTIC in 1 BOX (0407-2943-17... 376.9 mg/mL 1,500 $135.00 — ● Active CMS ASP
00407-2943-22 CLARISCAN gadoterate meglumine 376.9 mg/mL INJECTION, SOLUTION GE 10 SYRINGE, PLASTIC in 1 BOX (0407-2943-22... 376.9 mg/mL 2,000 $180.00 — ● Active CMS ASP
00407-2943-70 CLARISCAN gadoterate meglumine 376.9 mg/mL INJECTION, SOLUTION GE 10 BOTTLE, PLASTIC in 1 BOX (0407-2943-70)... 376.9 mg/mL 10,000 $900.00 — ● Active CMS ASP
65219-0080-05 Gadoterate Meglumine 376.9 mg/mL INJECTION Fresenius 10 CARTON in 1 BOX (65219-080-05) / 1 VIA... 376.9 mg/mL 500 $45.00 — ● Active CMS ASP
65219-0082-10 Gadoterate Meglumine 376.9 mg/mL INJECTION Fresenius 10 CARTON in 1 BOX (65219-082-10) / 1 VIA... 376.9 mg/mL 1,000 $90.00 — ● Active CMS ASP
65219-0084-15 Gadoterate Meglumine 376.9 mg/mL INJECTION Fresenius 10 CARTON in 1 BOX (65219-084-15) / 1 VIA... 376.9 mg/mL 1,500 $135.00 — ● Active CMS ASP
65219-0086-20 Gadoterate Meglumine 376.9 mg/mL INJECTION Fresenius 10 CARTON in 1 BOX (65219-086-20) / 1 VIA... 376.9 mg/mL 2,000 $180.00 — ● Active CMS ASP
65219-0088-50 Gadoterate Meglumine 376.9 mg/mL INJECTION Fresenius 6 CARTON in 1 BOX (65219-088-50) / 1 VIAL... 376.9 mg/mL 6,000 $540.00 — Obsolete CMS ASP
67684-2000-00 DOTAREM gadoterate meglumine 376.9 mg/mL INJECTION Guerbet 10 VIAL in 1 PACKAGE (67684-2000-0) / 5 m... 376.9 mg/mL 500 $45.00 — ● Active CMS ASP
67684-2000-01 DOTAREM gadoterate meglumine 376.9 mg/mL INJECTION Guerbet 10 VIAL in 1 PACKAGE (67684-2000-1) / 10... 376.9 mg/mL 1,000 $90.00 — ● Active CMS ASP
67684-2000-05 Dotarem Guerbet — — 500 $45.00 — — CMS ASP
67684-2000-06 Dotarem Guerbet — — 750 $67.50 — — CMS ASP
67684-2001-00 DOTAREM gadoterate meglumine 376.9 mg/mL INJECTION Guerbet 10 VIAL in 1 PACKAGE (67684-2001-0) / 5 m... 376.9 mg/mL 500 $45.00 — ● Active CMS ASP
67684-2001-01 DOTAREM gadoterate meglumine 376.9 mg/mL INJECTION Guerbet 10 VIAL in 1 PACKAGE (67684-2001-1) / 10... 376.9 mg/mL 1,000 $90.00 — ● Active CMS ASP
67684-2001-02 DOTAREM gadoterate meglumine 376.9 mg/mL INJECTION Guerbet 10 VIAL in 1 PACKAGE (67684-2001-2) / 15... 376.9 mg/mL 1,500 $135.00 — ● Active CMS ASP
67684-2001-03 DOTAREM gadoterate meglumine 376.9 mg/mL INJECTION Guerbet 10 VIAL in 1 PACKAGE (67684-2001-3) / 20... 376.9 mg/mL 2,000 $180.00 — ● Active CMS ASP
67684-2001-04 DOTAREM gadoterate meglumine 376.9 mg/mL INJECTION Guerbet 6 VIAL in 1 PACKAGE (67684-2001-4) / 100... 376.9 mg/mL 6,000 $540.00 — ● Active CMS ASP
67684-3001-01 DOTAREM gadoterate meglumine 376.9 mg/mL INJECTION Guerbet 10 SYRINGE, PLASTIC in 1 PACKAGE (67684-30... 376.9 mg/mL 1,000 $90.00 — ● Active CMS ASP
67684-3001-02 DOTAREM gadoterate meglumine 376.9 mg/mL INJECTION Guerbet 10 SYRINGE, PLASTIC in 1 PACKAGE (67684-30... 376.9 mg/mL 1,500 $135.00 — ● Active CMS ASP
67684-3001-03 DOTAREM gadoterate meglumine 376.9 mg/mL INJECTION Guerbet 10 SYRINGE, PLASTIC in 1 PACKAGE (67684-30... 376.9 mg/mL 2,000 $180.00 — ● Active CMS ASP
70436-0123-31 gadoterate meglumine 376.9 mg/mL INJECTION Slate 10 VIAL in 1 CARTON (70436-123-31) / 5 mL... 376.9 mg/mL 500 $45.00 — ● Active CMS ASP
70436-0123-33 gadoterate meglumine 376.9 mg/mL INJECTION Slate 10 VIAL in 1 CARTON (70436-123-33) / 10 m... 376.9 mg/mL 1,000 $90.00 — ● Active CMS ASP
70436-0123-34 gadoterate meglumine 376.9 mg/mL INJECTION Slate 10 VIAL in 1 CARTON (70436-123-34) / 15 m... 376.9 mg/mL 1,500 $135.00 — ● Active CMS ASP
70436-0123-35 gadoterate meglumine 376.9 mg/mL INJECTION Slate 10 VIAL in 1 CARTON (70436-123-35) / 20 m... 376.9 mg/mL 2,000 $180.00 — ● Active CMS ASP
70436-0123-56 gadoterate meglumine 376.9 mg/mL INJECTION Slate 6 VIAL in 1 CARTON (70436-123-56) / 100 m... 376.9 mg/mL 6,000 $540.00 — ● Active CMS ASP
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)

Period
Total Part B spend
$1.45M
Claims
91,951
Beneficiaries
88,579
Spend / beneficiary
$16.40
Spend / claim
$15.79
Trend by period
Where A9575 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #351 of 824
#346 EPOPROSTENOL SODIUM* J1325 $1.5M #347 LEXISCAN* J2785 $1.48M #348 ABILIFY MAINTENA J0401 $1.47M #349 GADAVIST* A9585 $1.46M #350 NUSHIELD 1 SQUARE CM... Q4160 $1.46M #351 CLARISCAN* A9575 $1.45M #352 FLUCELVAX * 90661 $1.4M #353 AFLURIA (3YR UP)* 90656 $1.4M #354 BORTEZOMIB(J9041)* J9041 $1.38M #355 MYOBLOC J0587 $1.33M #356 FASLODEX* J9395 $1.32M
Total claims — #27 of 824
#22 PAVBLU Q5147 107,941 #23 EVENITY (2 SYRINGES) J3111 106,087 #24 IPRATROPIUM-ALBUTERO... J7620 105,195 #25 BOTOX COSMETIC* J0585 104,273 #26 DIPHENHYDRAMINE HCL J1200 97,723 #27 CLARISCAN* A9575 91,951 #28 ALBUTEROL SULFATE(J7... J7613 86,874 #29 BUDESONIDE* J7626 84,831 #30 DARZALEX FASPRO J9144 82,545 #31 SPIKEVAX * 91322 76,644 #32 AVASTIN J9035 74,904

Full breakdown by period (2)
PeriodTotal spendBeneficiariesClaims$/beneficiary$/claim
2026 (Q1) $1.45M 88,579 91,951 $16.40 $15.79
2025 (Q1-Q4) $6.64M 334,113 377,032 $19.87 $17.61
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$6.71M
Medicare paid
$5.2M
Submitted services
58,314,008
Denial rate
5.7%
Allowed / service
$0.12
Submitted charges
$77.06M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

🗺️ Where A9575 is utilized CMS · BY PROVIDER · 2024

Medicare Part B services for this code by the rendering provider's state — 53,453,861 services across 54 states & territories in 2024 (CMS reports include DC and U.S. territories). Switch to per 100k to compare states fairly regardless of population. Hover or tap a state for its top ZIP codes.
Hover or tap a state to see its numbers + top ZIP codes.
Per-capita = services ÷ 2023 state population × 100,000 (so high-population states aren't automatically "hotter"). Counts reflect the provider's location, not the patient's. Providers with fewer than 11 patients are hidden by CMS for privacy, so totals run low and per-100k can be noisy in small states — read this as relative geography, not exact counts. Source: CMS Medicare Physician & Other Practitioners — by Provider and Service, 2024.

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Not available in current dataset
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-09-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
30 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ A9575 billing FAQ

What is HCPCS code A9575?
A9575 is a HCPCS Level II J-code used to bill Inj gadoterate meglumi 0.1ml under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for A9575?
One unit of A9575 represents 0.1 ML. Report the number of units equal to the dose administered divided by 0.1 ML.
How many units of A9575 should I bill?
Divide the dose administered by the code's unit size (0.1 ML) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for A9575?
The Medicare Part B payment limit is $0.090 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $0.088 per unit. Payment limits are revised quarterly.
Which NDCs bill under A9575?
30 NDCs currently map to A9575 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean A9575 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.